The Brigham is giving advanced heart failure patients a new option that parallels the life prolongation of heart transplantation: implantation of a fully magnetically levitated left ventricular assist device. Mandeep R. Mehra, MD, and Akinobu Itoh, MD, PhD, are at the forefront of these efforts.

Scott D. Solomon, MD, director of the Clinical Trials Outcomes Center at Brigham and Women’s Hospital, and colleagues have concluded that SGLT2 inhibitors should be considered adjunctive therapy for all patients with heart failure, regardless of ejection fraction or care setting.

In a prespecified secondary analysis of the DELIVER trial, Scott D. Solomon, MD, at Brigham and Women’s Hospital, and colleagues found that starting dapagliflozin during or shortly after hospitalization for HF is safe and effective for patients with mildly reduced or preserved ejection fraction.

On November 5—7, 2022, experts from the Brigham’s Heart and Vascular Center will join thousands of colleagues in raising awareness and improving cardiovascular health at this year’s American Heart Association (AHA) Scientific Sessions.

Brigham researchers confirmed that non-heart failure (HF) hospitalizations are burdensome for patients who have HF with preserved ejection fraction (HFpEF), who tend to have more noncardiac comorbidities than patients who have HF with reduced ejection fraction.

A team led by Brigham investigators has reported findings from a study looking at whether heart failure patients with mildly reduced or preserved ejection fraction could benefit from treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin. First author Scott David Solomon, MD, shares his perspective.

An international research team co-led by Christine E. Seidman, MD, found that molecular and cellular mechanisms of heart failure in patients with dilated cardiomyopathy or arrhythmogenic cardiomyopathy were determined by the specific gene variant each individual carried.